198 related articles for article (PubMed ID: 23756858)
1. Intratumoral concentration of estrogens and clinicopathological changes in ductal carcinoma in situ following aromatase inhibitor letrozole treatment.
Takagi K; Ishida T; Miki Y; Hirakawa H; Kakugawa Y; Amano G; Ebata A; Mori N; Nakamura Y; Watanabe M; Amari M; Ohuchi N; Sasano H; Suzuki T
Br J Cancer; 2013 Jul; 109(1):100-8. PubMed ID: 23756858
[TBL] [Abstract][Full Text] [Related]
2. DCIS and aromatase inhibitors.
Dixon JM; Faratian D; White S; Renshaw L; Murray J; Young O; Macaskill EJ; Williams L; Thomas J; Evans DB
J Steroid Biochem Mol Biol; 2007; 106(1-5):173-9. PubMed ID: 17604618
[TBL] [Abstract][Full Text] [Related]
3. Anti-tumor effects of letrozole.
Miller WR; Anderson TJ; Dixon JM
Cancer Invest; 2002; 20 Suppl 2():15-21. PubMed ID: 12442345
[TBL] [Abstract][Full Text] [Related]
4. Phase II Single-Arm Study of Preoperative Letrozole for Estrogen Receptor-Positive Postmenopausal Ductal Carcinoma In Situ: CALGB 40903 (Alliance).
Hwang ES; Hyslop T; Hendrix LH; Duong S; Bedrosian I; Price E; Caudle A; Hieken T; Guenther J; Hudis CA; Winer E; Lyss AP; Dickson-Witmer D; Hoefer R; Ollila DW; Hardman T; Marks J; Chen YY; Krings G; Esserman L; Hylton N
J Clin Oncol; 2020 Apr; 38(12):1284-1292. PubMed ID: 32125937
[TBL] [Abstract][Full Text] [Related]
5. Changes in expression of oestrogen regulated and proliferation genes with neoadjuvant treatment highlight heterogeneity of clinical resistance to the aromatase inhibitor, letrozole.
Miller WR; Larionov A
Breast Cancer Res; 2010; 12(4):R52. PubMed ID: 20646288
[TBL] [Abstract][Full Text] [Related]
6. In situ aromatase expression in primary tumor is associated with estrogen receptor expression but is not predictive of response to endocrine therapy in advanced breast cancer.
Lykkesfeldt AE; Henriksen KL; Rasmussen BB; Sasano H; Evans DB; Møller S; Ejlertsen B; Mouridsen HT
BMC Cancer; 2009 Jun; 9():185. PubMed ID: 19531212
[TBL] [Abstract][Full Text] [Related]
7. Postmenopausal women with DCIS post-mastectomy: a potential role for aromatase inhibitors.
Chlebowski RT; Col N
Breast J; 2012; 18(4):299-302. PubMed ID: 22681627
[TBL] [Abstract][Full Text] [Related]
8. A randomised study of the effects of letrozole and anastrozole on oestrogen receptor positive breast cancers in postmenopausal women.
Murray J; Young OE; Renshaw L; White S; Williams L; Evans DB; Thomas JS; Dowsett M; Dixon JM
Breast Cancer Res Treat; 2009 Apr; 114(3):495-501. PubMed ID: 18438705
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of Letrozole as First-Line Treatment of Postmenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer in Korea.
Beom SH; Oh J; Kim TY; Lee KH; Yang Y; Suh KJ; Moon HG; Han SW; Oh DY; Han W; Kim TY; Noh DY; Im SA
Cancer Res Treat; 2017 Apr; 49(2):454-463. PubMed ID: 27554482
[TBL] [Abstract][Full Text] [Related]
10. An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.
Henriksen KL; Rasmussen BB; Lykkesfeldt AE; Møller S; Ejlertsen B; Mouridsen HT
Acta Oncol; 2009; 48(4):522-31. PubMed ID: 19173092
[TBL] [Abstract][Full Text] [Related]
11. Relationship of body mass index with aromatisation and plasma and tissue oestrogen levels in postmenopausal breast cancer patients treated with aromatase inhibitors.
Lønning PE; Haynes BP; Dowsett M
Eur J Cancer; 2014 Apr; 50(6):1055-64. PubMed ID: 24507547
[TBL] [Abstract][Full Text] [Related]
12. Biology of aromatase inhibitors: pharmacology/endocrinology within the breast.
Miller WR
Endocr Relat Cancer; 1999 Jun; 6(2):187-95. PubMed ID: 10731108
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant tamoxifen and aromatase inhibitors: comparisons and clinical outcomes.
Dixon JM; Jackson J; Renshaw L; Miller WR
J Steroid Biochem Mol Biol; 2003 Sep; 86(3-5):295-9. PubMed ID: 14623524
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.
Rasmussen BB; Regan MM; Lykkesfeldt AE; Dell'Orto P; Del Curto B; Henriksen KL; Mastropasqua MG; Price KN; Méry E; Lacroix-Triki M; Braye S; Altermatt HJ; Gelber RD; Castiglione-Gertsch M; Goldhirsch A; Gusterson BA; Thürlimann B; Coates AS; Viale G;
Lancet Oncol; 2008 Jan; 9(1):23-8. PubMed ID: 18083065
[TBL] [Abstract][Full Text] [Related]
15. The role of aromatase inhibitors in the management of ductal carcinoma in situ with an estrogen receptor-positive/progesterone receptor-negative/Her-2/neu receptor-positive pattern.
Altundag K; Bulut N; Sari E; Harputluoglu H
Am J Surg; 2007 Aug; 194(2):272-3. PubMed ID: 17618822
[No Abstract] [Full Text] [Related]
16. Phase II trial with letrozole to maximum response as primary systemic therapy in postmenopausal patients with ER/PgR[+] operable breast cancer.
Llombart-Cussac A; Guerrero Á; Galán A; Carañana V; Buch E; Rodríguez-Lescure Á; Ruiz A; Fuster Diana C; Guillem Porta V
Clin Transl Oncol; 2012 Feb; 14(2):125-31. PubMed ID: 22301401
[TBL] [Abstract][Full Text] [Related]
17. The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model.
Long BJ; Jelovac D; Thiantanawat A; Brodie AM
Clin Cancer Res; 2002 Jul; 8(7):2378-88. PubMed ID: 12114443
[TBL] [Abstract][Full Text] [Related]
18. Local endocrine effects of aromatase inhibitors within the breast.
Miller WR; Dixon JM
J Steroid Biochem Mol Biol; 2001 Dec; 79(1-5):93-102. PubMed ID: 11850212
[TBL] [Abstract][Full Text] [Related]
19. Biomarker changes associated with the development of resistance to aromatase inhibitors (AIs) in estrogen receptor-positive breast cancer.
Arnedos M; Drury S; Afentakis M; A'Hern R; Hills M; Salter J; Smith IE; Reis-Filho JS; Dowsett M
Ann Oncol; 2014 Mar; 25(3):605-610. PubMed ID: 24525703
[TBL] [Abstract][Full Text] [Related]
20. Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer.
Allevi G; Strina C; Andreis D; Zanoni V; Bazzola L; Bonardi S; Foroni C; Milani M; Cappelletti MR; Gussago F; Aguggini S; Giardini R; Martinotti M; Fox SB; Harris AL; Bottini A; Berruti A; Generali D
Br J Cancer; 2013 Apr; 108(8):1587-92. PubMed ID: 23579222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
